

TECHNOLOGIEPARK BASEL

Zielgruppe des Technologieparks Basel sind innovative Jungunternehmen aus der Life Sciences-Industrie, der chemischen Industrie, der Umwelt- und Energietechnologie, der Nanotechnologie sowie der Informations- und Kommunikationstechnologie. Die Unternehmen werden auf Basis ihres Innovationspotenzials sowie ihres Potenzials, mittelfristig Arbeitsplätze in der Region zu schaffen und Wertschöpfung zu generieren, ausgewählt.

Der kommerzielle Start dieser Jungunternehmen aus Hochtechnologiebranchen wird durch das Angebot von Büro-, Labor- und Lagerflächen sowie Infrastrukturen zur gemeinschaftlichen Nutzung vereinfacht. Zudem stellt der Technologiepark Basel grundlegende Dienstleistungen zur Verfügung.

Erfolgreiche Jungunternehmen bleiben oft nur wenige Jahre im Technologiepark Basel. Nach Etablierung des Unternehmens und dessen Produkten im Markt finden die Unternehmen einen neuen Standort im regionalen Immobilienmarkt.

Der Technologiepark Basel ist nicht gewinnorientiert, sondern ist ein Instrument der baselstädtischen Standortförderung. Im Verbund mit weiteren Instrumenten leistet er einen Beitrag zur Erhöhung der Zahl der in der Region Basel neu gegründeten Hochtechnologie-Unternehmen.

ERSTE UND ZWEITE ERWEITERUNG TECHNOLOGIEPARK BASEL

Aufgrund der grossen Nachfrage und um den Expansionsplänen der bestehenden Mieter gerecht zu werden, wurde der Technologiepark Basel im Sommer 2014 zum ersten Mal erweitert. Neben einer Verdopplung der Labor- und Büroflächen wurden auch ein zentraler Empfangsbereich sowie ein Auditorium erstellt.

Die anhaltend hohe Auslastung der Labor- und Büroflächen im Technologiepark Basel sowie die Verfügbarkeit von freien Flächen im gleichen Gebäude haben dazu geführt, dass der Regierungsrat und der Grosse Rat des Kantons Basel-Stadt einer zweiten Erweiterung des Technologieparks Basel zugestimmt haben. Anfang 2018 wurde die Fläche um weitere 12 Biologie- und 2 Chemielabors, 34 Büros sowie weitere Gemeinschaftsräume (Sitzungszimmer, Küche, Aufenthaltsbereiche sowie Geräte- und Waschräume) erweitert, so dass der Technologiepark Basel aktuell gesamthaft rund 6400 m² Fläche umfasst.

FACTS & FIGURES

Juristische Einheit

Technologiepark Basel AG, gegründet am 31. März 2011

Eigentümer & Aktionär

Kanton Basel-Stadt

Verwaltungsrat

Samuel Hess (Präsident), Robert-Jan Bumbacher (Vizepräsident), Nina Ryser-Iten (Mitglied)

Geschäftsleitung und Team

Der Verwaltungsrat delegiert die Geschäftsleitung des Technologieparks Basel an Nina Ryser-Iten (Leitung Standortförderung im Amt für Wirtschaft und Arbeit). Weiter sind Christian Harr (Operativer Leiter), Brigitte Jäggi (Administration), Güney Talas (Empfang) und Giovanni Attianese (Techn. Mitarbeiter) für den Technologiepark Basel tätig.

Eröffnung des Technologieparks Basel

Sommer 2011, 1. Erweiterung Sommer 2014, 2. Erweiterung Anfang 2018

Vermietungsstand per 31. Dezember 2017

86%

Fläche

Seit Sommer 2014: ca. 3400 m²

Seit Anfang 2018: ca. 6400 m²

Mietflächen

Büroflächen ab 12m²

Laborflächen ab 43m²

Mietpreise

Die Mietpreise im Technologiepark Basel liegen auf Marktniveau. Der Technologiepark Basel bietet innovativen Jungunternehmen aber zum Beispiel durch kurze Kündigungsfristen, der Verfügbarkeit von kleinen Mietflächen und der unentgeltlichen Vorhaltung von Expansionsflächen vorteilhafte Mietkonditionen.

Partner

Kanton Basel-Stadt, Swisscom

Kontakt

Technologiepark Basel AG

Hochbergerstrasse 60C

4057 Basel

Tel.: +41 61 633 22 00

www.technologiepark.ch

Mieter im Technologiepark



BioVersys AG, www.bioversys.com

BioVersys switches off bacterial drug resistance, thus reactivating approved antibiotics.

We develop small chemical molecules, which switch off drug resistance on a gene regulatory level within bacteria, so called TRIC's (Transcriptional Regulator Inhibitory Compounds). Current pipeline: Gram negative and positive bacteria; Tuberculosis.



NBE-Therapeutics GmbH, www.NBE-Therapeutics.com

NBE-Therapeutics is a new Swiss Life-Sciences company focused on the development of novel antibody-based therapeutics. NBE-Therapeutics utilizes a portfolio of in-house developed, externally acquired, and in-licensed novel patent families for the development of novel, best-in-class antibody drug conjugates (ADCs), that can specifically target cancer cells for destruction.



Ramirez Engineering GmbH,

Ramirez Engineering GmbH is a Hard- & Firmware Engineering company, specialized in standard and custom specific developments. In addition to devices for Industrial applications, we are also specialized in developing and manufacturing KNX devices, the worldwide standard for home and building control. In this way, we help reducing energy waste in Offices and Hotels Worldwide.



abel-systems, www.abel-systems.ch

abel-systems is a software engineering and IT consulting company specialized in custom web and mobile development. abel-systems develops and distributes the process- and document-management solution QM-Pilot. Furthermore we provide IT solutions for content management, web and mobile apps, as well as the development of individual solutions with modern technologies.



Intilaris LifeSciences GmbH, www.intilaris.com

Intilaris LifeSciences is a life science company focusing on productivity improvements and optimizations in Clinical development of pharmaceutical companies. The company provides GCP consulting and develops tools and systems that will lead to better utilization of the current resources and optimization of the clinical development processes. The customers of intilaris LifeSciences are the Clinical Development organizations of research oriented pharmaceutical companies. To a wider extend, intilaris LifeSciences serves the Clinical Development organizations of research oriented biotechnology companies as well.



Cray Computer GmbH, www.cray.com

As a global leader in supercomputing, Cray provides highly advanced systems and solutions and world-class service and support to government, industry and academia. Cray technology enables scientists and engineers to not only meet existing and future simulation and analytics challenges but achieve remarkable breakthroughs by accelerating performance, improving efficiency and extending the capabilities of their most demanding applications.



PIQUR AG, www.piquor.com

PIQUR Therapeutics is a privately owned biopharmaceutical company, headquartered in Basel, Switzerland, that is pioneering the development of a novel class of targeted therapeutics. PIQUR is dedicated to the development of oncology products that can improve the lives and outcomes of cancer patients.

The company was founded in 2011 as a spin-off of the University of Basel (Switzerland) to develop best-in-class, new generation cancer therapeutics targeting the PI3K-Akt-mTOR pathway. With its next generation agents, PIQUR is confident to be the leader in the development of drugs tackling the PI3K cancer pathway.



Hutman Diagnostics AG, www.hutman.com

Hutman Diagnostics is an *in Vitro* Diagnostics Product Development and Portfolio Management Company in particular, Hutman Diagnostics develops next generation diagnostic kits for life-threatening pathogens so far diagnosed mainly by classical culture. The new diagnostics shorten the time for medical decision to less than 4 hours while having inclusivity of nearly 100%. This will save health costs and shorten the time to cure.



FGen GmbH, www.fgen.ch

FGen is a service provider for biotechnology, life-sciences, and industry. The company was founded in 2011 by Prof. Sven Panke (Bioprocess Laboratory of the Department of Biosystems Science and Engineering of the ETH Zurich in Basel) and a number of his scientific fellows. FGen develops and performs high throughput experiments and assays on a contract basis for its customers from biotech, pharma, and chemical industries.



STREKIN AG, www.strekin.com

Strekin AG is a private company located in Basel. We identify and develop differentiated medicines for diseases linked to stress related inflammatory pathways by scientific cross disease area target assessment.

Cellestia Biotech S.A., www.cellestiabiotech.com.com



Cellestia Biotech S.A. is a private biopharmaceutical company with strategic focus on anti-cancer drugs modulating the NOTCH signalling pathway. CB-103 is a novel, first-in-class, oral pan-Notch inhibitor for treatment of NOTCH dependent leukemia, lymphoma and solid tumors.



Aurealis Pharma AG., www.aurealispharma.com

AUREALIS PHARMA

Aurealis Pharma is a Swiss-Finnish biopharmaceutical company with a technology platform facilitating combination therapy embedded in one single product that can be administered in a safe, efficient and cost-effective way. Safe food-grade lactic acid bacteria release multiple therapeutic human proteins locally in diseased tissue. Our first products are immunotherapeutics to treat patients with chronic inflammatory wounds and cancer indications.
Aurealis



Halozyme Switzerland GmbH., www.halozyme.com

Halozyme is a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. Our lead proprietary program, the investigational drug PEGPH20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. By breaking down potential barriers to treating cancer, PEGPH20 may help make existing treatments more effective by allowing therapies to reach the tumor.



Douglas Connect GmbH., www.douglasconnect.com

Douglas Connect manages collaborative projects to achieve goals in scientific research, infrastructure development or service provision. Douglas Connect acts both as the initiator of independent research projects (eg. in Discovery Informatics, Knowledge Management, Life Sciences, Drug Safety, Environmental Chemistry, Risk Assessment) and as a provider of integrated services for corporate clients in these areas.

The logo for VAXIMM, featuring the word "VAXIMM" in a bold, blue, sans-serif font.

Vaximm AG, www.vaximm.com

VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer.

VAXIMM's technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens.

The logo for accurato., featuring the word "accurato." in a lowercase, blue, sans-serif font with a period at the end.

Innovation Lab for Digital Solutions

accurato ag, www.accurato.ch

accurato provides help to our clients Digital Transformation journey with Consulting, Business Analysis, Project- and Service Management as well as Product-, Service- and Solutions Development in the fields of Mobile Applications, Data Centres, Cloud and Cyber Security.



Ridgeline

A Versant Discovery Engine

Ridgeline Therapeutics AG

Ridgeline is Versant's newest discovery engine and has laboratories in Basel Technology Park. Ridgeline's leadership team hails from Roche and has a proven track record in drug development



DayOne, www.dayone.swiss

DayOne - the innovation hub for precision medicine has a vision to "Create a world leading precision medicine hub respected for its impact and collaboration across silos."

The logo for kinarus, featuring the word "kinarus" in a bold, blue, lowercase, sans-serif font.

KINARUS AG, www.kinarus.com

KINARUS AG is a private company located in Basel. We identify and develop differentiated medicines for diseases linked to stress related inflammatory pathways by scientific cross disease area target assessment.

TargImmune Therapeutics AG



TargImmune Therapeutics AG is a startup company established in March 2016 in Basel, Switzerland. TargImmune is developing a novel cancer-targeted platform technology CTPIC in the field of immuno-oncology and personalized therapy

Health Care Systems GmbH (HCSG), www.hcsg.de



Making patient data smart - HCSG offers solutions for digital precision medicine.

We combine medical data with psychosocial data creating actionable information and risk predictions to improve individual health outcomes. Our highly flexible IT platform allows large scale implementation for a multitude of patient conditions and care situations.

Nuomedis AG / ARTIDIS



Nuomedis AG focuses on development and commercialization of ARTIDIS (AUTOMATED AND RELIABLE TISSUE DIAGNOSTICS) nanotechnology platform for rapid diagnostics and treatment optimization. ARTIDIS is based on the atomic force microscope, which can determine the (nano)mechanical properties of native tissue by using a fine, nanometer-scale probe. able to examine tissue biopsies within an hour. By providing such nanomechanical profile of patient biopsy sample, ARTIDIS allows for rapid diagnosis of benign or malignant tumors and consequently optimization of treatment for cancer patients.